Current Research Studies
PEDIATRIC AND YOUNG ADULT LEUKEMIA ADOPTIVE THERAPY (PLAT)-07: A PHASE 1/2 STUDY OF CD22-SPECIFIC CAR T CELLS FOR CD22+ LEUKEMIA OR LYMPHOMA
PLAT-07
What is the goal of the study?
This phase 1/2, open-label, non-randomized study will enroll pediatric and young adult research participants with relapsed or refractory CD22+ leukemia or lymphoma with and without prior history of allogeneic hematopoietic stem cell transplantation, to examine the safety, feasibility, and efficacy of administering T cell products derived from autologous peripheral blood mononuclear cells (PBMC) that have been genetically modified using a self-inactivating SIN lentiviral vector to express a CD22-specific chimeric antigen receptor (CAR), and the selection-suicide marker EGFRt (SCRI-CAR22v2).
Who can participate in the study?
Please contact the study team listed below to learn more.